Payment overview · 2025
General Payments
$303.04
16 reported records · 9 companies
Healthcare provider profile · identity verified
Joy Hinnant, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Community Health · ROCKY MOUNT, NC · NPI 1932864949
Verified facts
What the public records show
CMS Open Payments records show Joy Hinnant, FNP-C received $303.04 in general payments during 2025 across 16 reported records.
Corcept Therapeutics accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $115.24 | 38.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.71 | 15.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.06 | 11.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.56 | 7.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.48 | 6.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.47 | 5.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.59 | 5.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.37 | 5.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.56 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $303.04 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $115.24 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 194 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
194 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 642 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 189 |
| Hydrochlorothiazide | Hydrochlorothiazide | 291 | 93 |
| Gabapentin | Gabapentin | 235 | 92 |
| Omeprazole | Omeprazole | 209 | 60 |
| Farxiga | Dapagliflozin Propanediol | 194 | 50 |
| Losartan Potassium | Losartan Potassium | 191 | 62 |
| Furosemide | Furosemide | 188 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 72 |
| Lisinopril | Lisinopril | 177 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 41 |
| Famotidine | Famotidine | 140 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 32 |
| Ozempic | Semaglutide | 125 | 18 |
| Metformin Hcl Er | Metformin Hcl | 123 | 41 |
| Trulicity | Dulaglutide | 122 | 23 |
| Meloxicam | Meloxicam | 116 | 43 |
| Metformin Hcl | Metformin Hcl | 116 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 45 |
| Jardiance | Empagliflozin | 102 | 31 |
| Eliquis | Apixaban | 99 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 98 | 41 |
| Carvedilol | Carvedilol | 91 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 33 |
| Potassium Chloride | Potassium Chloride | 81 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 20 |
| Trazodone Hcl | Trazodone Hcl | 74 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 67 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 26 |
| Allopurinol | Allopurinol | 62 | 23 |
| Simvastatin | Simvastatin | 62 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 25 |
| Ibuprofen | Ibuprofen | 59 | 31 |
| Lovastatin | Lovastatin | 59 | 18 |
| Tramadol Hcl | Tramadol Hcl | 59 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 17 |
| Ezetimibe | Ezetimibe | 57 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 18 |
| Linzess | Linaclotide | 51 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 17 |
| Prednisone | Prednisone | 49 | 34 |
| Meclizine Hcl | Meclizine Hcl | 48 | 17 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 16 |
| Finasteride | Finasteride | 42 | 12 |
| Nitroglycerin | Nitroglycerin | 37 | 15 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Naproxen | Naproxen | 34 | 12 |
| Valsartan | Valsartan | 33 | 13 |
| Baclofen | Baclofen | 32 | 11 |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Glipizide | Glipizide | 30 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | 11 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ibu | Ibuprofen | 26 | 16 |
| Nystatin | Nystatin | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Spironolactone | Spironolactone | 22 | 11 |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Risperidone | Risperidone | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $303.04 · 16 records | Corcept Therapeutics | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, Kerendia, Korlym, MAVYRET, MOUNJARO, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error